Methamphetamine Hcl (methamphetamine HCl)

Dosage and potency of methamphetamine hydrochloride are expressed in terms of the hydrochloride.

Dosage of methamphetamine hydrochloride should be adjusted according to individual response and tolerance; the smallest dose required to produce the desired response should always be used.

When possible, interrupt therapy occasionally to determine if there is recurrence of behavioral symptoms sufficient to require continued treatment.

Methamphetamine hydrochloride is administered orally. Because of the potential for insomnia, administration of methamphetamine in the late evening should be avoided.

Methamphetamine hydrochloride preparations should be stored in tight, light-resistant, child-resistant containers at 20-25degreesC.

No dosing information is available for this tab.

No dosing information is available for this tab.

Amphetamines and amphetamine derivatives are metabolized to some extent by cytochrome P-450 (CYP) isoenzyme 2D6, and to a minor extent, inhibit CYP2D6 metabolism.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

*Concomitant or recent (within 14 days) administration of monoamine oxidase inhibitors (MAOIs), since hypertensive crisis could result.

*Known hypersensitivity to amphetamine, or any ingredient in methamphetamine hydrochloride tablets. Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients taking other amphetamine products.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

Adverse effects reported with the use of methamphetamine include blood pressure elevations, tachycardia/heart palpitations, and fatal cardiopulmonary arrest in the context of drug abuse/misuse. Additionally, psychotic episodes, dizziness, dysphoria, overstimulation, euphoria, insomnia, tremor, restlessness, headache, exacerbation of motor and verbal tics and Tourette's syndrome, diarrhea, constipation, dry mouth, unpleasant taste, intestinal ischemia, and other GI disturbances have been reported. Urticaria, impotence and libido changes, frequent or prolonged erections, rhabdomyolysis, suppression of growth in children with long-term use, and alopecia have also been reported.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

The safety and efficacy of methamphetamine for ADHD have not been established in children <6 years of age.

Long-term therapy with CNS stimulants may be associated with suppression of growth in children.

The National Pregnancy Registry for ADHD Medications monitors pregnancy outcomes in women exposed to ADHD medications during pregnancy. Clinicians are encouraged to register women who become pregnant while receiving methamphetamine by calling 866-961-2388 or visiting https://womensmentalhealth.org/adhdmedications/.

Methamphetamine has been shown to have teratogenic and embryocidal effects in mammals receiving doses exceeding the usual therapeutic human dosage. There are no adequate and controlled studies to date in pregnant women. Methamphetamine should not be used during pregnancy unless the potential benefits justify the possible risks to the fetus.

Infants born to women dependent on amphetamines have an increased risk of premature delivery and low birth weight. Infants born to mothers receiving amphetamines during pregnancy may also experience symptoms of withdrawal such as dysphoria, agitation, and significant lassitude.

Amphetamines are distributed into human milk. Breastfeeding should be avoided during therapy with amphetamines.

The manufacturer does not provide specific dosage recommendations for geriatric patients. Due to the greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease or drug therapy, dosage selection for geriatric patients should be cautious, usually starting at the low end of the dosage range.

Clinical studies of methamphetamine did not include sufficient numbers of patients >=65 years of age to determine whether geriatric patients respond differently than younger patients. While other reported clinical experience has not revealed age-related differences in response, dosage selection for geriatric patients should be cautious, usually starting at the low end of the dosage range. The greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease or drug therapy observed in this population also should be considered.